source
- Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic diseaseCaspian Therapeutics, a spin‑out from Kura Oncology, announced it is starting operations with $50 million in financing. The capital, led by BVF Partners and joined by Eli Lilly and Kura leadership,…
- FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque, but patients face delayed accessThe U.S. Food and Drug Administration has granted approval to Rasonque, a new therapy for pancreatic cancer developed by Revolution Medicines. The decision follows clinical data that showed the dru…